Table 1.
Clinical, demographic, and sample characteristics of pwCF (n = 16) on/off ETI therapy (n = 7/9)
| Subject ID | ETI | Days on ETI | Period (days) between the first sample and ETI | Samples collected | BMI | Gender | ppFEV1 PP (%) | FVC PP (%) | Pathogen cultures (Sputum) |
|---|---|---|---|---|---|---|---|---|---|
| 001 | No | – | 104 | 18.9 | F | 54.4 | 73.8 | – | |
| 002 | No | – | 36 | 27.5 | M | 54.8 | 73.1 | – | |
| 003 | No | – | 114 | 23.0 | M | 38.7 | 48.3 | Pa, Sa | |
| 004 | No | – | 75 | 20.6 | F | 52.9 | 63.4 | Pa, Ac | |
| 005 | No | – | 190 | 29.0 | M | 69.6 | 91.1 | Steno | |
| 006 | No | – | 90 | 18.5 | F | 52.0 | 78.4 | – | |
| 007 | No | – | 17 | 30.2 | F | 50.0 | 60.0 | Pa, Sa, Ac, Strep | |
| 008 | No | – | 20 | 21.5 | F | 52.0 | 70.0 | Pa, Sa | |
| 009 | No | – | 15 | 22.1 | M | 40.0 | 66.0 | Pa | |
| 010 | Yes | 537 | 277 | 18 | 27.3 | F | 111.0 | 114.0 | Pa, Sa |
| 011 | Yes | 286 | 163 | 40 | 27.9 | M | 79.0 | 100.0 | Pa, Sa, Steno, Strep |
| 012 | Yes | 454 | 226 | 20 | 20.2 | F | 67.0 | 84.0 | Pa, Sa, Strep |
| 013 | Yes | 453 | 345 | 13 | 23.3 | F | 72.0 | 75.0 | Pa, Sa, Bc, |
| 014 | Yes | 227 | 103 | 35 | 20.7 | F | 53.0 | – | Bc |
| 015 | Yes | 426 | 326 | 15 | 22.4 | F | 52.0 | 70.0 | Pa |
| 016 | Yes | 377 | 210 | 21 | 23.2 | F | 101.0 | 107.0 | Pa, Sa |
Subjects id’s information (001-006) was obtained from [18]. ETI treatment status as well as the time (days) on treatment since started until the last sample collection, body mass index (BMI), gender, highest predicted lung function (ppFEV1 and FVC), and pathogen cultures within sputum are presented. Pathogen results are abbreviated as follows: Pseudomonas aeruginosa (Pa), Staphylococcus aureus (Sa), Burkholderia cepacia (Bc), Achromobacter sp. (Ac), Stenotrophomonas sp. (Steno) and Streptococcus sp. (Strep). The subject’s IDs were decoded as serial numbers to keep the anonymity and privacy of participants.